483
Mitsubishi Tanabe Pharma Development America, Inc.FDA 483 - Mitsubishi Tanabe Pharma Development America, Inc. - October 15, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Mitsubishi Tanabe Pharma Development America, Inc. in Jersey City, NJ, identified two significant issues related to post-marketing adverse drug experience reporting. The firm lacked written procedures for reporting periodic safety reports, including quarterly and annual reports. Additionally, the company failed to submit two quarterly periodic adverse drug experience reports for Exservan within the required timeframe.
- Inspection Date
- October 15, 2021
- Product Type
- Drugs
Open in Dashboard
ID · 40f73b79-76f1-4878-a034-b697a60dcaaa